Radical External-Beam Radiotherapy in Combination With Intracavitary Brachytherapy for Localized Carcinoma of the Cervix in Sri Lanka: Is Treatment Delayed Treatment Denied?


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
10 2020
Historique:
entrez: 20 10 2020
pubmed: 21 10 2020
medline: 29 7 2021
Statut: ppublish

Résumé

Radical external-beam radiotherapy (EBRT) followed by intracavitary brachytherapy is standard of care for patients with localized carcinoma of the cervix unsuitable for radical surgery. However, outcome data are scarce in resource-limited settings. We conducted a retrospective analysis of survival in a cohort of patients treated with this strategy in Sri Lanka. All patients with localized cervical cancer treated with primary EBRT and intracavitary brachytherapy from 2014 to 2015 were included in the study. Primary end point was disease-free survival (DFS), defined as time to local or systemic recurrence or death. Univariable analysis was performed to determine the prognostic significance of the following variables: age, stage, use of concurrent chemotherapy, EBRT dose, brachytherapy dose, and time to completion of treatment (dichotomized at 60 days). Factors significant on univariable analysis were included in a multivariable model. A total of 113 patients with available data were included in the analysis. Mean age was 58 years (range, 35-85 years), and most patients (n = 103 of 113) presented with stage ≥ IIB disease. Median time to delivery of brachytherapy from commencement of EBRT was 110 days (range, 34-215 days), with only 12 (11%) of 113 patients completing treatment within 60 days. Median follow-up was 28 months (range, 5-60 months), and 2-year DFS was 63.7% (95% CI, 55.4% to 73.2%). Treatment delay was the only significant factor associated with inferior DFS on univariable analysis (log-rank There are significant delays in receiving intracavitary brachytherapy after completing EBRT for cervical cancer in Sri Lanka, which is associated with inferior DFS. Increasing brachytherapy resources is an urgent priority to improve outcomes of patients with cervical cancer.

Identifiants

pubmed: 33079608
doi: 10.1200/GO.20.00196
pmc: PMC7605371
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1574-1581

Références

J Clin Oncol. 2008 Dec 10;26(35):5802-12
pubmed: 19001332
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):466-470
pubmed: 31540589
Int Health. 2014 Jun;6(2):138-43
pubmed: 24737803
JAMA Oncol. 2018 Apr 1;4(4):506-513
pubmed: 29423520
Br J Radiol. 2010 Jul;83(991):554-68
pubmed: 20603408
BMC Cancer. 2014 Feb 21;14:116
pubmed: 24558979
BMC Public Health. 2015 Nov 25;15:1179
pubmed: 26608133
Radiother Oncol. 1992 Dec;25(4):273-9
pubmed: 1480773
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):201-11
pubmed: 10924990
Ann Oncol. 2012 Oct;23 Suppl 7:vii27-32
pubmed: 22997451
J Natl Compr Canc Netw. 2010 Dec;8(12):1358-86
pubmed: 21147902
Int J MCH AIDS. 2012;1(1):17-30
pubmed: 27621956
Clin Microbiol Rev. 2003 Jan;16(1):1-17
pubmed: 12525422

Auteurs

Nuradh Joseph (N)

General Hospital Chilaw, Ministry of Health, Chilaw, Sri Lanka.
Sri Lanka Cancer Research Group, Maharagama, Sri Lanka.

Hasanthi Jayalath (H)

Sri Lanka Cancer Research Group, Maharagama, Sri Lanka.
General Hospital Matara, Ministry of Health, Matara, Sri Lanka.

Jayantha Balawardena (J)

Faculty of Medicine, Sir John Kotalawela Defence University, Rathmalana, Sri Lanka.

Thurairajah Skandarajah (T)

Sri Lanka Cancer Research Group, Maharagama, Sri Lanka.
Apeksha Hospital, Ministry of Health, Maharagama, Sri Lanka.

Kanthi Perera (K)

Sri Lanka Cancer Research Group, Maharagama, Sri Lanka.
Apeksha Hospital, Ministry of Health, Maharagama, Sri Lanka.

Dehan Gunasekera (D)

Sri Lanka Cancer Research Group, Maharagama, Sri Lanka.
Apeksha Hospital, Ministry of Health, Maharagama, Sri Lanka.

Sujeeva Weerasinghe (S)

Sri Lanka Cancer Research Group, Maharagama, Sri Lanka.
Apeksha Hospital, Ministry of Health, Maharagama, Sri Lanka.

Peter Hoskin (P)

Mount Vernon Cancer Center, Northwood, United Kingdom.
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Ananya Choudhury (A)

The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH